Aculys

Aculys Pharma, Inc. is a Japanese clinical-stage biopharmaceutical company focused on neurological and psychiatric diseases where there is high unmet medical need. The company works to eliminate Japan's drug lag and drug loss by bringing innovative medicines already approved in Western markets to Japanese patients as early as possible. Its lead product is Spydia (diazepam nasal spray), Japan's first domestically developed intranasal anti-seizure agent, approved in June 2025 and administrable outside medical facilities. Originally funded by SoftBank Vision Fund (Series C, March 2025), Aculys was acquired by and became part of the Viatris Group in October 2025. Aculys publishes no public developer program, API, or technical documentation surface; this profile is maintained for network completeness and identity.

Aculys is profiled on the APIs.io network. Tagged areas include Company, Health Tech, Pharmaceuticals, Biotech, and Neurology.

Aculys’ developer surface includes engineering blog and 8 more developer resources.

🌐 Visit website 📡 Source on GitHub

12.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

0 APIs

CompanyHealth TechPharmaceuticalsBiotechNeurologyJapan

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 12.8/100 · minimal

Contract Quality 0.0 / 25

Developer Ergonomics 0.4 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 1.4 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/aculys: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Access & Security 2

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

SecurityPolicy

SecurityPolicy

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy

PrivacyPolicy

TermsOfService

TermsOfService

Company 4

The organization behind the API

Website

Website

Blog

Blog

About

About

LinkedIn

Other 1

Properties that don't map to a standard resource type

Products

Products

Source (apis.yml)

aid: aculys
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/aculys.png
name: Aculys
description: Aculys Pharma, Inc. is a Japanese clinical-stage biopharmaceutical company focused on neurological and psychiatric
  diseases where there is high unmet medical need. The company works to eliminate Japan's drug lag and drug loss by bringing
  innovative medicines already approved in Western markets to Japanese patients as early as possible. Its lead product is
  Spydia (diazepam nasal spray), Japan's first domestically developed intranasal anti-seizure agent, approved in June 2025
  and administrable outside medical facilities. Originally funded by SoftBank Vision Fund (Series C, March 2025), Aculys was
  acquired by and became part of the Viatris Group in October 2025. Aculys publishes no public developer program, API, or
  technical documentation surface; this profile is maintained for network completeness and identity.
url: https://raw.githubusercontent.com/api-evangelist/aculys/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- softbank-vision-fund
x-acquired-by: viatris
x-tier: stub
x-tier-reason: portfolio-lead
x-api-surface: none
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Health Tech
- Pharmaceuticals
- Biotech
- Neurology
- Japan
apis: []
common:
- type: DomainSecurity
  url: security/aculys-domain-security.yml
- type: Website
  url: https://aculys.com/en/
- type: Blog
  url: https://aculys.com/en/news/
- type: About
  url: https://aculys.com/en/company/
- type: Products
  url: https://aculys.com/en/our-products/
- type: PrivacyPolicy
  url: https://aculys.com/en/privacy-policy/
- type: TermsOfService
  url: https://aculys.com/en/terms-and-conditions
- type: SecurityPolicy
  url: https://aculys.com/en/security-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/aculys/about/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence